Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy

Autor: Yen-Yang Chen, Pei-Hung Chang, Shun-Wen Hsueh, Pei-Wei Huang, Yu-Shin Hung, Kun-Yun Yeh, Wen-Chi Chou, Jen-Shi Chen, Chang-Hsien Lu, Chia-Yen Hung, Ching-Fu Chang
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
Male
Cancer Research
medicine.medical_treatment
pancreatic cancer
Deoxycytidine
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Medicine
prognostic model
Original Research
Aged
80 and over
Hazard ratio
Palliative Care
palliative chemotherapy
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
Drug Combinations
Treatment Outcome
030220 oncology & carcinogenesis
Female
medicine.drug
medicine.medical_specialty
Combination therapy
lcsh:RC254-282
03 medical and health sciences
Young Adult
Internal medicine
Pancreatic cancer
Humans
Radiology
Nuclear Medicine and imaging
Aged
Proportional Hazards Models
Retrospective Studies
Tegafur
Chemotherapy
business.industry
Clinical Cancer Research
Palliative chemotherapy
Models
Theoretical
medicine.disease
Survival Analysis
Gemcitabine
Confidence interval
Pancreatic Neoplasms
Regimen
Oxonic Acid
030104 developmental biology
business
Zdroj: Cancer Medicine
Cancer Medicine, Vol 8, Iss 12, Pp 5554-5563 (2019)
ISSN: 2045-7634
Popis: Background We previously developed a robust prognostic model (GS model) to predict the survival outcome of patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy with gemcitabine plus S‐1 (GS). This study aimed to validate the application of the GS model in APC patients receiving chemotherapy other than the GS regimen. Patients and methods We retrospectively analyzed 727 APC patients who received first‐line palliative chemotherapy other than the GS regimen between 2010 and 2016 at four institutions in Taiwan. The patients were categorized into three prognostic groups based on the GS model for comparisons of survival outcome, best tumor response, and in‐group survival differences with monotherapy or combination therapy. Results The median survival times for the good, intermediate, and poor prognostic groups were 13.4, 8.4, and 4.6 months, respectively. The hazard ratios for the comparisons of intermediate and poor to good prognostic groups were 1.51 (95% confidence interval [CI]), 1.22‐1.88, P
This study provided validation of the previously developed gemcitabine + S‐1 model in predicting the survival outcome of advanced pancreatic cancer patients receiving first‐line palliative chemotherapy.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje